Journal of NeuroVirology

, Volume 21, Issue 6, pp 645–652

JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients

Authors

  • Serena Delbue
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
  • Francesca Elia
    • Laboratory of Translational Research Fondazione Ettore Sansavini
  • Camilla Carloni
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
  • Valentina Pecchenini
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
  • Diego Franciotta
    • Department of General NeurologyNational Neurological Institute C. Mondino
  • Matteo Gastaldi
    • Department of General NeurologyNational Neurological Institute C. Mondino
  • Elena Colombo
    • Department of General NeurologyNational Neurological Institute C. Mondino
  • Lucia Signorini
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
  • Silvia Carluccio
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
  • Anna Bellizzi
    • Department of Public Health and Infectious DiseasesSapienza University
  • Roberto Bergamaschi
    • Department of General NeurologyNational Neurological Institute C. Mondino
    • Istituto Clinico Città Studi
    • Department of Biomedical Surgical and Dental SciencesUniversity of Milano
Article

DOI: 10.1007/s13365-014-0268-0

Cite this article as:
Delbue, S., Elia, F., Carloni, C. et al. J. Neurovirol. (2015) 21: 645. doi:10.1007/s13365-014-0268-0

Abstract

The risk of developing progressive multifocal leukoencephalopathy (PML), as a consequence of infection/reactivation with JC virus (JCV), is consistent in natalizumab-treated multiple sclerosis (MS) patients, with 430 cases of PML reported so far. The risk of PML is higher in JCV seropositive patients, and it is recommended that only MS patients without JCV antibodies should be enrolled in the treatment postulating that they do not have JCV infection.

We have studied forty-two natalizumab-treated MS patients, and urine and blood were collected monthly for up to 60 months. JCV and BK virus (BKV) DNA presence was verified using quantitative real-time PCR assays, and serum anti-JCV antibodies were measured with the Stratify and/or Stratify DxSelect tests.

JCV and BKV DNA were not found in the blood samples, whereas they were found at least once in the urine of 21 of 42 (50 %) and of 25/42 (59.5 %) patients, respectively. JCV DNA urinary shedding increased up to month 24 of natalizumab treatment (45.2 %), and the effect of time was significant for JCV (p = 0.04), but not for BKV (p = 0.39). JCV viruria and seropositivity did not completely correlate, since three patients shedding JCV DNA in the urine were seronegative according to the serological tests.

The results indicated that natalizumab therapy may increase the rate of JCV urinary shedding. Additionally, we confirmed that the identification of JCV carriers cannot solely rely on serological tests, but sensitive methods for viral DNA detection should be adopted to more precisely identify the truly JCV uninfected cases.

Keywords

NatalizumabJC virusMultiple sclerosisUrinary excretionSeroprevalence

Copyright information

© Journal of NeuroVirology, Inc. 2014